External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition

9Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least likely to experience immune-related adverse events (irAE) has driven an extensive search for predictive biomarkers. Here, we externally validate the performance of 59 previously reported markers of irAE risk in a new cohort of 110 patients receiving Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA-4) therapy. Alone or combined, the discriminatory value of these routine clinical parameters and flow cytometry biomarkers was poor. Unsupervised clustering of flow cytometry data returned four T cell subsets with higher discriminatory capacity for colitis than previously reported populations, but they cannot be considered as reliable classifiers. Although mechanisms predisposing some patients to particular irAEs have been described, we are presently unable to capture adequate information from pre-therapy flow cytometry and clinical data to reliably predict risk of irAE in most cases.

References Powered by Scopus

Regularization and variable selection via the elastic net

13105Citations
N/AReaders
Get full text

Regularization paths for generalized linear models via coordinate descent

12226Citations
N/AReaders
Get full text

Nonparametric statistical methods

6167Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

30Citations
N/AReaders
Get full text

Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

16Citations
N/AReaders
Get full text

Innate immunity and early liver inflammation

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Glehr, G., Riquelme, P., Yang Zhou, J., Cordero, L., Schilling, H. L., Kapinsky, M., … Kronenberg, K. (2022). External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1011040

Readers over time

‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

50%

Engineering 2

50%

Save time finding and organizing research with Mendeley

Sign up for free
0